A Clinical Study on the Efficacy and Safety of Zeprumetostat in Relapsed/Refractory Large Granular Lymphocyte Leukemia

Polatuzumab Vedotin Boosts Survival in Relapsed DLBCL

Phase I CARLYSLE study: CAR T-cell therapy obe-cel shows favorable safety and clinical benefit in severe refractory lupus

This article reports initial results from the phase I CARLYSLE study evaluating obecabtagene autoleucel (obe-cel), a CD19-targeting CAR T-ce

FDA advisory panel makes favorable recommendation for ARZERRA (ofatumumab)

GlaxoSmithKline and Genmab submit Arzerra (Ofatumumab) application to FDA for the treatment of advanced stage blood cancer

Donor-derived stem cell memory CAR T cells show enhanced expansion and safety in post-HSCT relapse treatment

This first-in-human study (NCT01087294) investigates donor-derived CD19-CAR T cells for treating B cell malignancies relapsing after allogen

The Evolving Role of Targeted Therapies in Chronic Lymphocytic Leukemia Care